Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Agrippal Influenza Vaccine (2008-2009) in Adults
NCT00748813Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2008
- Primary completion
- Jul 2008
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of subunit inactivated influenza vaccine in seasonal influenza, sponsored by Novartis. Primary endpoint: Antibody response to each influenza vaccine antigen at Day 21. Started Jun 2008; status: completed.
02
Drugs
subunit inactivated influenza vaccine
03
Conditions
seasonal influenza
Beyond the preview
Go deeper on NCT00748813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00748813.